DBV Technologies
29 rue du Faubourg
Saint Jacques
Paris
75014
France
Tel: 33-0-1-55-389270
Fax: 33-0-1-41-312882
Website: http://www.dbv-technologies.com/
Email: info@dbv-technologies.com
207 articles about DBV Technologies
-
DBV Technologies Announces Data Presentations For EPIT At The European Academy Of Allergy And Clinical Immunology (EAACI) Congress 2014
3/25/2014
-
DBV Technologies Technologies Reports Full Year 2013 Financial Results And Provides VIPES Update
3/17/2014
-
DBV Technologies Release: Presentation And Publication Of Research At American Academy of Allergy, Asthma and Immunology (AAAAI) Demonstrates EPIT(TM)'S Ability To Rebalance The Immune System And Induce A Disease-Modifying Effect
3/5/2014
-
DBV Technologies To Present At The Barclays Global Healthcare Conference In Miami, USA
3/4/2014
-
DBV Technologies And Mount Sinai Hospital Enter Research Collaboration For Crohn's Disease
2/18/2014
-
DBV Technologies Reports Full Year 2013 Topline Financial Results
1/30/2014
-
DBV Technologies To Present Key Scientific Publications At The American Academy Of Allergy, Asthma & Immunology (AAAAI) Annual Conference
1/29/2014
-
DBV Technologies Provides 2013 Year-End Summary And News Flow Guidance For 2014
12/17/2013
-
DBV Technologies Enters Into Collaboration Agreement With Bionet-Asia And University of Geneva On Whooping Cough Booster Vaccine
11/26/2013
-
National Institutes of Health (NIH)-Sponsored Consortium of Food Allergy Research (CoFAR) Starts a Phase 2 Clinical Study With DBV Technologies' ViaskinĀ® Peanut in the Treatment of Peanut Allergy
10/24/2013
-
DBV Technologies Forms Research Collaboration With INSERM to Develop ViaskinĀ® for Refractory Hemophilia A Disease
10/23/2013
-
Stallergenes, S.A. Inks $198 Million Pact for Allergy R&D With DBV Technologies
10/18/2013
-
DBV Technologies Announces Topline Financial Results for First Nine Months 2013 and Provides Safety Update on ViaskinĀ® Peanut
10/15/2013
-
Company Profile for DBV Technologies
9/27/2013
-
DBV Technologies Initiates a Long-Term Follow-Up Study of Viaskin Peanut
9/4/2013
-
DBV Technologies Reports Financial Results for the First Six Months of 2013
7/26/2013
-
DBV Technologies Completes Enrollment of Phase IIb VIPES Study, the First-Ever Global Trial in Desensitization to Peanut Allergy
7/8/2013
-
DBV Technologies: Viaskin Peanut Demonstrates Strong Efficacy Trend in Severely Peanut-Allergic Children in 18-Month Results of ARACHILD Pilot Study
6/21/2013
-
DBV Technologies Proudly Welcomes Mrs. Veronique Foutel as Chief Strategic Marketing Officer
6/6/2013
-
DBV Technologies and Stallergenes, S.A. Enter Into Partnership for the Development of Innovative Treatment of Respiratory Allergies
5/17/2013